A5101519988- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Planetary Science and Exploration
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Bone health and treatments
- Astro and Planetary Science
- Cancer Treatment and Pharmacology
- Agriculture Sustainability and Environmental Impact
- Hormonal and reproductive studies
- Geochemistry and Geologic Mapping
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Child Nutrition and Water Access
- Geological and Geochemical Analysis
- Statistical Methods in Clinical Trials
- Geology and Paleoclimatology Research
- Multiple Myeloma Research and Treatments
- Space Exploration and Technology
- Isotope Analysis in Ecology
- Hydrocarbon exploration and reservoir analysis
- Management of metastatic bone disease
- Genetic factors in colorectal cancer
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Xylem (United States)
2025
Chesapeake Bay Program
2024
Elizabeth River Project
2024
U.S. Army Engineer Research and Development Center
2024
Australian Government
2023
Emory University
2022
Film Independent
2022
KPMG (United Kingdom)
2021
Apalutamide, a competitive inhibitor of the androgen receptor, is under development for treatment prostate cancer. We evaluated efficacy apalutamide in men with nonmetastatic castration-resistant cancer who were at high risk metastasis.We conducted double-blind, placebo-controlled, phase 3 trial involving and prostate-specific antigen doubling time 10 months or less. Patients randomly assigned, 2:1 ratio, to receive (240 mg per day) placebo. All patients continued androgen-deprivation...
Circulating signals of drug resistance Cancer drugs often lose their effectiveness because tumors acquire genetic changes that confer resistance. Ideally, patients would be switched to a different before tumor growth resumes, but this requires early knowledge how arose. Miyamoto et al. have developed non-invasive method spot by sequencing RNA transcripts in single circulating cells (CTCs) (see the Perspective Nanus and Giannakakou). For example, prostate cancer patients, was triggered...
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients nonmetastatic, castration-resistant prostate cancer. Whether combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase metastatic, hormone-sensitive cancer unknown.
Rare circulating tumor cells (CTCs) are present in the blood of patients with metastatic epithelial cancers but have been difficult to measure routinely. We report a quantitative automated imaging system for analysis prostate CTCs, taking advantage prostate-specific antigen (PSA), unique tumor-associated marker. The specificity PSA staining enabled optimization criteria baseline image intensity, morphometric measurements, and integration multiple signals three-dimensional microfluidic...
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear hormone that plays key role in the differentiation of adipocytes. Activation this liposarcomas and breast colon cancer cells also induces cell growth inhibition differentiation. In present study, we show PPARγ expressed human prostate adenocarcinomas lines derived from these tumors. with specific ligands exerts an inhibitory effect on lines. Further, do not have intragenic mutations gene, although 40% informative tumors...
Understanding dietary patterns is vital to reducing the number of people experiencing hunger (about 795 million), micronutrient deficiencies (2 billion), and overweight or obesity (2.1 billion). We characterize global trends in quality by estimating density food supply, prevalence inadequate intake 14 micronutrients, average these micronutrients for all countries between 1961 2011. Over this 50-year period, estimated intakes has declined regions due increased total production and/or density....
Abstract Purpose: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) detects superior sensitivity imaging, but its performance nmCRPC remains largely unknown. We characterized burden high-risk using PSMA-PET....
The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, improved median metastasis-free survival (MFS) by 2 yr overall (OS) data were immature. We report the prespecified event-driven final analysis for OS. A total 1207 nmCRPC (diagnosed conventional imaging) randomised 2:1 to (240 mg/d) or placebo, plus on-going androgen deprivation...
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including
BackgroundIncreasing atmospheric concentrations of carbon dioxide (CO2) affect global nutrition via effects on agricultural productivity and nutrient content food crops. We combined these with economic projections to estimate net changes in availability between 2010 2050.MethodsIn this modelling study, we used the International Model for Policy Analysis Agricultural Commodities Trade project per capita protein, iron, zinc 2050. estimated individual commodities model production, trade,...
12 Background: Approximately 20% of mCRPC has alterations in genes associated with HRR and is responsive to PARP inhibitors (PARPi) such as NIRA. Combined PARPi androgen receptor pathway targeting may also benefit unselected mCRPC. MAGNITUDE assessed whether adding NIRA AAP improves outcomes pts or without genes. Methods: (NCT03748641) a randomized, double-blind phase 3 study. In eligible pts, ≤4 mos prior for was allowed. Pts (HRR biomarker [BM]+; ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2,...
Patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations have poor outcomes. MAGNITUDE found patients homologous recombination repair gene (HRR+), particularly BRCA1/2, benefit from first-line therapy niraparib plus abiraterone acetate prednisone (AAP). Here we report longer follow-up the second prespecified interim analysis (IA2).
In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time symptomatic progression in patients high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overall (OS) results at first interim analysis (IA1) were immature, 104 of 427 (24%) events required for planned final OS analysis. Here, we report a second pre-specified (IA2).
Insufficient data exist for accurate estimation of global nutrient supplies. Commonly used datasets contain key weaknesses: 1) with coverage, such as the FAO food balance sheets, lack specific information about many individual foods and no on micronutrient supplies nor heterogeneity among subnational populations, while 2) household surveys provide a closer approximation consumption, but are often not nationally representative, do commonly capture consumed outside home, only adequate few...
Abstract Blood-based biomarkers are critical in metastatic prostate cancer, where characteristic bone metastases not readily sampled, and they may enable risk stratification localized disease. We established a sensitive high-throughput strategy for analyzing circulating tumor cells (CTC) using microfluidic cell enrichment followed by digital quantitation of prostate-derived transcripts. In prospective study 27 patients with castration-resistant cancer treated first-line abiraterone,...